108 related articles for article (PubMed ID: 10762660)
1. Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients.
Cao Y; Veitonmaki N; Keough K; Cheng H; Lee LS; Zurakowski D
Int J Mol Med; 2000 May; 5(5):547-51. PubMed ID: 10762660
[TBL] [Abstract][Full Text] [Related]
2. Angiostatin fragments in urine from patients with malignant disease.
Sten-Linder M; Linder C; Strander H; Munck-Wikland E; Wersäll P; Linder S; Wiman B
Anticancer Res; 1999; 19(4C):3409-14. PubMed ID: 10629628
[TBL] [Abstract][Full Text] [Related]
3. Low levels of endostatin in the urine from patients with malignant disease.
Linder-Stragliotto C; Strander H; Munck-Wikland E; Sten-Linder M
Tumour Biol; 2002; 23(4):222-7. PubMed ID: 12499778
[TBL] [Abstract][Full Text] [Related]
4. Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action.
Sharma MR; Rothman V; Tuszynski GP; Sharma MC
Exp Mol Pathol; 2006 Oct; 81(2):136-45. PubMed ID: 16643891
[TBL] [Abstract][Full Text] [Related]
5. Macrophage formation of angiostatin during inflammation. A byproduct of the activation of plasminogen.
Falcone DJ; Khan KM; Layne T; Fernandes L
J Biol Chem; 1998 Nov; 273(47):31480-5. PubMed ID: 9813061
[TBL] [Abstract][Full Text] [Related]
6. Diurnal variations in angiostatin in human tear fluid: a possible role in prevention of corneal neovascularization.
Sack RA; Beaton AR; Sathe S
Curr Eye Res; 1999 Mar; 18(3):186-93. PubMed ID: 10342373
[TBL] [Abstract][Full Text] [Related]
7. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells.
Stathakis P; Fitzgerald M; Matthias LJ; Chesterman CN; Hogg PJ
J Biol Chem; 1997 Aug; 272(33):20641-5. PubMed ID: 9252380
[TBL] [Abstract][Full Text] [Related]
8. Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin.
Tarui T; Majumdar M; Miles LA; Ruf W; Takada Y
J Biol Chem; 2002 Sep; 277(37):33564-70. PubMed ID: 12087108
[TBL] [Abstract][Full Text] [Related]
9. The role of angiostatin in the spontaneous bone and prostate cancers of pet dogs.
Pirie-Shepherd SR; Coffman KT; Resnick D; Chan R; Kisker O; Folkman J; Waters DJ
Biochem Biophys Res Commun; 2002 Apr; 292(4):886-91. PubMed ID: 11944897
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta 1 inhibits generation of angiostatin by human pancreatic cancer cells.
O'Mahony CA; Albo D; Tuszynski GP; Berger DH
Surgery; 1998 Aug; 124(2):388-93. PubMed ID: 9706163
[TBL] [Abstract][Full Text] [Related]
11. Different inhibitors of plasmin differentially affect angiostatin production and angiogenesis.
Hatziapostolou M; Katsoris P; Papadimitriou E
Eur J Pharmacol; 2003 Jan; 460(1):1-8. PubMed ID: 12535853
[TBL] [Abstract][Full Text] [Related]
12. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth.
O'Reilly MS
EXS; 1997; 79():273-94. PubMed ID: 9002223
[TBL] [Abstract][Full Text] [Related]
13. Limited plasmin proteolysis of vitronectin. Characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor.
Kost C; Benner K; Stockmann A; Linder D; Preissner KT
Eur J Biochem; 1996 Mar; 236(2):682-8. PubMed ID: 8612645
[TBL] [Abstract][Full Text] [Related]
14. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.
Stack MS; Gately S; Bafetti LM; Enghild JJ; Soff GA
Biochem J; 1999 May; 340 ( Pt 1)(Pt 1):77-84. PubMed ID: 10229661
[TBL] [Abstract][Full Text] [Related]
15. Differential production of angiostatin by concomitant antitumoral resistance-inducing cancer cells.
Binda MM; Matar P; González AD; Rozados VR; Gervasoni SI; Scharovsky OG; Bonfil RD
Int J Cancer; 2002 Jul; 100(1):14-21. PubMed ID: 12115581
[TBL] [Abstract][Full Text] [Related]
16. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin.
Gately S; Twardowski P; Stack MS; Patrick M; Boggio L; Cundiff DL; Schnaper HW; Madison L; Volpert O; Bouck N; Enghild J; Kwaan HC; Soff GA
Cancer Res; 1996 Nov; 56(21):4887-90. PubMed ID: 8895739
[TBL] [Abstract][Full Text] [Related]
17. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.
Gately S; Twardowski P; Stack MS; Cundiff DL; Grella D; Castellino FJ; Enghild J; Kwaan HC; Lee F; Kramer RA; Volpert O; Bouck N; Soff GA
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10868-72. PubMed ID: 9380726
[TBL] [Abstract][Full Text] [Related]
18. Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin.
Stathakis P; Lay AJ; Fitzgerald M; Schlieker C; Matthias LJ; Hogg PJ
J Biol Chem; 1999 Mar; 274(13):8910-6. PubMed ID: 10085135
[TBL] [Abstract][Full Text] [Related]
19. Enzyme-linked immunosorbent assay for the specific detection of angiostatin-like plasminogen moieties in biological samples.
Lijnen HR; Bloemmen F; Vereecken A; Collen D
Thromb Res; 2001 Apr; 102(1):53-9. PubMed ID: 11323015
[TBL] [Abstract][Full Text] [Related]
20. Purification and characterization of A61. An angiostatin-like plasminogen fragment produced by plasmin autodigestion in the absence of sulfhydryl donors.
Kassam G; Kwon M; Yoon CS; Graham KS; Young MK; Gluck S; Waisman DM
J Biol Chem; 2001 Mar; 276(12):8924-33. PubMed ID: 11114303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
